jakafi domin ultra-rare-diseas indic
updat forecast estim apr
lead drug jakafi initi gain traction drug
approv sever myelofibrosi mf rare blood disord
jakafi monopoli mf market like continu
especi two lead competitor drug left play
field lacklust pivot trial data expand jakafi
label polycythemia vera pv late evalu
drug essenti thrombocythemia et steroid refractori acut
graft versu host diseas agvhd push peak
sale billion
anoth near-term driver jak inhibitor olumi baricitinib
approv europ rheumatoid arthriti earli
partner estim ra
billion-plu market repres compel opportun oral
treatment like olumi could significantli increas
treatment penetr rate grow market oral jak
inhibitor xeljanz first market believ safeti concern
may weigh market penetr leav opportun
olumi cleaner safeti profil take share near
term compani also robust late-stag pipelin focus
primarili oncolog autoimmun indic provid
attract long-term growth opportun firm
face major trial failur believ rest compani
robust pipelin support long-term growth trajectori
use cash gener success jakafi franchis
build suit asset evalu combin
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research apr
estim apr
price data apr
rate updat apr
currenc amount express
valuat growth profit
methodolog valu compani
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
focus discoveri develop small-molecul drug
firm lead drug jakafi treat two type rare blood cancer
partner novarti market drug includ rheumatoid
arthriti treatment olumi licens oncolog
drug iclusig chronic myeloid leukemia pipelin includ broad
array oncolog autoimmun program includ next-gener jak
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
valuat growth profit apr
lower fair valu estim
per share light epacadostat phase trial
failur metastat melanoma combin merck
inhibitor keytruda remov incyt ido
inhibitor program model anticip lacklust
result remain trial evalu epacadostat
combin checkpoint
differ oncolog indic posit readout
partnership astrazeneca bristol would
provid upsid fair valu estim
jakafi continu strong perform mf pv
discontinu sanofi mf candid
well lacklust pivot
result gilead momelotinib cti pharma/baxalta
pacritinib believ jakafi near-term growth prospect
improv drug signific first-mov
advantag product could come
think approv jakafi polycythemia vera
potenti label expans essenti thrombocythemia
acut gvhd could lead peak sale billion
next-gener itacitinib could mitig potenti
pipelin gener competit futur
updat model reflect olumi approv
europ assum drug gain approv
base eli lilli resubmit
applic drug market
receiv royalti percentag sale
addit develop regulatori mileston
 approv translat royalti revenu near
billion toward end forecast period
also optimist compani partnership
checkpoint modul program direct gitr
howev yet attribut
valu model enter early-stag
given depend hand market
drug regulatori commerci risk pipelin
believ firm warrant high uncertainti rate
bull-cas scenario assum jakafi success
expand indic greater optim
pipelin candid greater oper leverag
result per share fair valu estim
bear-cas scenario model jakafi struggl
penetr mpn market failur earli stage
asset oper cost result signific
financi burden base case result fair
valu drop per share
myeloprolif neoplasm mpn market
includ mf pv merit narrow econom moat rate
firm heavili depend jakafi sale nearli
revenu recent hit profit within
past year howev lack near-term threat
jakafi domin mf pv popul
incyt strong price power give us confid
compani gener return cost capit
forese futur
strong competit posit thank
jakafi franchis myeloprolif neoplasm
treatment approv food drug
administr myelofibrosi approv
polycythemia vera refractori patient drug
signific price power first-mov advantag
compet pipelin treatment jakafi solid efficaci
safeti profil patient popul high unmet
need allow compani set averag annual price
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
threat incyt jakafi franchis
robust pipelin mitig threat
futur jakafi sale compani sever early-
late-stag candid focus primarili oncolog
inhibitor provid
think posit moat trend base
potenti jakafi label expans progress
compani robust early-stag pipelin jakafi carv
strong defens market posit
addit label expans pv drug achiev
blockbust statu label expans acut chronic
graft-versus-host-diseas et could boost futur
given oral dose efficaci profil drug
receiv modest setback fda dose concern
complet respons letter earli believ
olumi eventu gain approv market
due high efficaci approv abbvi
phase competitor upadacitinib look
efficaci olumi ra base top-lin result
high standard compani procur
candid immuno-oncolog target posit
well increasingli key therapeut area
compani also sever earlier-stag candid focus
primarili oncolog autoimmun indic
recent partner checkpoint modul
program direct gitr
opportun remain rel unproven incyt
healthi pipelin give firm margin error
world-wide jakafi key patent expir
exclud potenti extens give incyt
signific runway build franchis expand
et gvhd indic
pipelin competit thin recent year
forese signific near-term threat
gilead drug momelotinib cti biopharma/baxalta
drug pacritinib previous led competit
acquisit impact biomedicin earli
celgen reviv anoth competitor program fedratinib
continu believ jakafi set high bar next round
novel molecul
myelofibrosi
lilli inhibitor gandotinib -- expect
use patient toler jakafi
low level platelet fail jakafi therapi
near-term prospect promis view mani
early-stag competitor trial underway includ
checkpoint inhibitor keytruda opdivo howev
believ earli candid signific
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
jakafi first fda-approv
treatment rare blood disord known
myelofibrosi give strong price power
oxeljanz delay european entri astrazeneca
abandon fostamatinib open door
baricitinib lead oral treatment
rheumatoid arthriti near term
broad array pipelin oncolog
autoimmun program give firm larger margin
error
market upend monopoli
ido inhibitor trial failur melanoma
remov key near-term asset pipelin
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
end nearli billion cash
market secur limit debt balanc
sheet howev like biotechnolog compani incyt
histor oper loss high cost
clinic trial research loss
financ larg offer equiti debt
secur collabor research develop fund
arrang develop mileston partner
despit heavi spend expect firm
reach sustain profit near term especi
jakafi sale intern royalti off-set
high invest
histor post loss due heavi
research develop spend firm current
sound financi shape prolong loss eros
jakafi sale could put financi posit jeopardi
signific risk mani drug candid
never reach market jakafi phase trial failur
pancreat cancer significantli reduc
optimist predict exampl addit new
competitor jakafi could reach market erod
competit posit drug also small
molecul ensur gener competit
difficult stave goe patent melanoma
trial failur highli anticip ido inhibitor
epacadostat combin merck inhibitor
keytruda also highlight development risk associ
biotech compani furthermor baricitinib
demonstr attract profil conveni oral
formul ra market highli competit
demonstr launch pfizer xeljanz
disappoint even though first oral
product market upadacitinib
demonstr clean safeti profil drug could give
olumi run money market
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
olumi yet approv
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
hoppenot took ceo join
presid oncolog novarti believ
hoppenot experi establish pharma firm
valuabl pipelin matur firm
transit one-drug start-up matur
diversifi biopharmaceut compani given firm
lack sustain profit past focus
deploy capit research develop
result capital-alloc decis
judg manag howev believ firm
licens agreement eli lilli olumi dictat
favor term compani sharehold alik
respons research
develop cost entitl substanti royalti
mileston payment although execut
 commerci jakafi well without previou
experi view think would
difficult go alon competit rheumatoid arthriti
market also like manag strategi deploy
cash gener jakafi franchis acquir early-stag
repres date owner name posit common share held report holder issuer
govern pension fund norway global
share
fund
share
fund
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
lower fve ido combo trial
follow-on previou note lower
fair valu estim per share
light epacadostat phase trial failur metastat
melanoma combin merck inhibitor
ido/checkpoint combin fail
improv progression-fre surviv keytruda alon
also appear unlik improv overal surviv
result remov incyt ido inhibitor program
model anticip lacklust result remain
trial evalu epacadostat combin
news major blow compani
believ market fail appreci incyt solid
jakafi franchis robust pipelin strategi beyond ido
program narrow moat rate rest jakafi
strong competit posit price power rare
diseas patient popul unaffect neg ido
underli decis remov futur sale
epacadostat combin model magnitud
trial failur well cautionari commentari
provid manag regard readthrough
ido trial wed stress neg
studi
epacadostat combin keytruda metastat
melanoma would necessarili translat immedi
discount rest incyt ido program across multipl
indic hazard ratio studi leav
direct inkl toward benefit keytruda alon
dampen outlook on-going studi test epacadostat
bristol opdivo astrazeneca imfinzi yet
read posit result could provid upsid
valuat howev optimist especi
manag explicitli call neg
impact probabl success studi
combin epacadostat weve adjust
oper expens account anticip shutter
remain ido program even outsid
melanoma align sg estim
fall line revis guidanc million
put fair valu estim
review adjust model recent disappoint
data ido inhibitor epacadostat weve previous
point epacadostat key driver compani
rate particularli see epacadostat data
on-going phase studi base jakafi entrench
posit myeloprolif neoplasm market
inclin leav narrow moat rate place
discuss note last week merck
announc phase studi
epacadostat combin keytruda metastat
melanoma fail combin unabl
improv progression-fre surviv keytruda alon
also unlik improv overal surviv hazard ratio
trend toward benefit compani
halt studi
earli data combin incyt ido inhibitor
merck keytruda melanoma promis
look like slightli better efficaci without addit
side effect drug combin trigger
manag still dive deeper see could
patient subgroup statu braf statu
better combin howev given
hazard ratio overal studi see similar
profil antibodi keytruda opdivo think
bode poorli epacadostat phase program
remain on-going
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
epacadostat failur blow merck
merck announc phase
studi epacadostat combin
keytruda metastat melanoma fail
combin unabl improv progression-fre surviv
keytruda alon unlik improv overal surviv
well hazard ratio trend toward
benefit compani halt studi expect
signific impact fair valu estim
weve previous point epacadostat
key driver compani valuat impact merck
mute compani alreadi establish
leader immuno-oncolog keytruda monotherapi
process launch gather data
combin keytruda variou regimen
earli data combin incyt ido inhibitor
merck keytruda melanoma promis
look like slightli better efficaci without addit
side effect drug combin trigger
manag still dive deeper see could
patient subgroup statu braf statu
better combin howev given
hazard ratio overal studi see similar
profil antibodi keytruda opdivo think
bode poorli epacadostat phase program
remain on-going
fve catalyst horizon feb
follow incyt fourth-quart result increas
fair valu estim per share reflect
time valu money updat estim cost
equiti revenu compani jakafi franchis
market jakavi outsid match
thank pipelin progress off-set higher
research develop cost believ incyt jak
inhibitor program includ jakafi next-gener
regimen strong efficaci first-in-class advantag
rare blood disord market uncertainti lead
pivot read-out incyt ido inhibitor drug combin
merck keytruda unfairli weigh compani
share view
total fourth-quart revenu grew year year
driven year-over-year growth jakafi sale
myelofibrosi patient continu major
contributor robust jakafi adopt continu uptak
polycythemia vera patient also tend stay
drug longer provid strong tailwind sequenti
basi jakafi sale roughli flat due announc
inventori stock third quarter despit news
celgen reviv competitor jak program fedratinib
remain confid jak franchis set
high bar new entrant model jakafi sale
toward bottom end manag billion
guidanc higher previou think limit
headwind result updat regul close
donut hole expect impact first-quart growth
although strong new patient demand remain key driver
jakafi sale potenti label expans acut graft-
versus-host-diseas year-end pend posit result
first half year provid anoth near-term
catalyst firm
eye peel upcom pivot result incyt
ido program advanc melanoma expect
first half key driver valuat
trial compar ido/checkpoint inhibitor
combin checkpoint inhibitor monotherapi
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
believ trial need show compar efficaci
ctla drug regimen margin weaker efficaci coupl
superior safeti profil ctla combin could
also keep ido regimen competit posit
risk neg read-out ido combin
melanoma optimist expect
result believ investor cautiou use
melanoma conclus directli read
rest incyt ido inhibitor program either way
compani sever phase trial evalu
epacadostat combin checkpoint inhibitor
keytruda merck opdivo bristol imfinzi astrazeneca
across number oncolog indic
addit potenti jakafi label expans pivot
epacadostat result anticip two addit catalyst
year includ fda approv eli lilly-partn
rheumatoid arthriti drug baracitinib
incyt intern develop fgfr inhibitor cholangiocarcinoma
type ultra-rar cancer end year believ
bar competitor like upadacitinib
boast similar top-line efficaci increas research
develop forecast reflect grow late-
pipelin progress prompt jump
fve share under-valued
thank impress pipelin progress third
quarter increas fair valu estim incyt
per share strong perform
revis full-year sale guidanc
billion billion previous
adjust estim margin midpoint
guidanc boost partial off-set higher-than-
expect research develop cost
incyt recent announc licens
inhibitor candid million mani incyt
partner program progress rapidli
develop posit well futur
believ compani merit narrow econom moat
rate base strong uptak jakafi rare blood
disord high unmet need littl pipelin
competit horizon fair valu chang
share look slightli under-valued nov
jakafi third-quart sale grew year-over-year
driven continu ramp polycythemia vera patient
popul healthi growth patient sever
myelofibrosi rais estim slightli
account faster-than-expect penetr
drug limit impact valuat incyt
partner rheumatoid arthriti drug olumiantwhich
approv europ japan expect
reach follow complet respons
letteri slow start believ oral option like
olumi add compel value-add patient current
encumb inject drug treatment label expans
jakafi steroid-refractori acut graft-versus-host-
diseas bodi reject donor transplant could
occur earli pend posit pivot result
addit expans essenti thrombocythemia would
boost forecast sale
incyt immuno-therapi portfolio led promis ido
inhibitor epacadostat continu attract flurri activ
larg pharma partner loath lose
next wave immuno-oncolog innov lead
pack merck combin trial evalu
inhibitor keytruda epacadostat
metastat
melanoma phase result expect first half
howev drug also progress
pivot test across legion indic combin
merck keytruda astrazeneca imfinzi
bristol opdivo roch
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
tecentriq given multitud program
enter pivot test increas cost estim
research develop effort next
mani larg pharma compani
early-stag in-hous ido inhibitor could vie
epacadostat lead long term optimist
pipelin strategi focus doublet tripl
regimen compani recent licens
candid low expect in-
hous candid monotherapi given
domin current incumb think move
ensur match slew novel early-stag drug
target gitr arginas inhibitor
larg pharma partner ever pull back
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
